| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary target of Fmoc-L-Ser((Ac)4-β-D-Glc)-OH is the growing peptide chain during solid-phase peptide synthesis, where it serves as a glycosylated amino acid building block. The compound is designed to incorporate O-glycosylated serine residues into synthetic peptides, enabling the study of glycoprotein structure and function. It does not target a specific biological receptor but rather serves as a tool for chemical biology research. The acetyl-protected glucose moiety allows for the synthesis of glycopeptides that can be deprotected to yield native O-glycosylated serine residues for biological studies.
|
|---|---|
| ln Vitro |
In vitro activity of this compound is assessed in the context of peptide synthesis rather than biological activity. The compound's reactivity is characterized by its ability to couple to resin-bound peptides under standard Fmoc-SPPS conditions. The coupling efficiency is monitored by the Kaiser test or other colorimetric assays. After deprotection of the acetyl groups, the resulting glycopeptide can be evaluated for its biological activity, such as binding to lectins or antibodies. The compound's utility lies in its ability to produce well-defined glycopeptides for studying protein glycosylation.
|
| ln Vivo |
In vivo biological activity is not applicable for this compound, as it is a synthetic intermediate used in peptide synthesis rather than a therapeutic agent. Its applications are confined to laboratory research in glycobiology and peptide chemistry. No in vivo efficacy or pharmacological studies in animal models are available, as the compound is not designed for systemic administration. The resulting glycopeptides may have biological activities, but the building block itself is not intended for in vivo use.
|
| Enzyme Assay |
Non-cellular experiments for this compound typically involve solid-phase peptide synthesis protocols. A typical procedure includes dissolving the Fmoc-protected amino acid in DMF with HBTU or HATU as the coupling reagent and DIEA as the base. The activated amino acid is then coupled to the resin-bound peptide for 1-2 hours. The coupling efficiency is monitored by the Kaiser test. After peptide assembly, the Fmoc group is removed with piperidine, and the acetyl groups are deprotected with hydrazine or sodium methoxide to yield the free glycopeptide.
|
| Cell Assay |
In vitro cell-based experiments are not typically performed with this compound, as it is a synthetic building block rather than a biological testing agent. However, the glycopeptides synthesized using this compound can be tested in cell-based assays to study their biological activities. For example, glycopeptides may be evaluated for their ability to bind to cell surface receptors or modulate immune responses. The compound itself is not tested in cell culture models for pharmacological activity.
|
| Animal Protocol |
In vivo animal studies are not performed with this compound in a therapeutic context. Its applications are confined to chemical synthesis and laboratory research. No efficacy or safety studies in animal models are available, as the compound is not intended for human or veterinary use. The glycopeptides synthesized using this compound may be tested in animals for their biological effects, but the building block itself is not administered directly.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not characterized for this compound, as it is a synthetic intermediate rather than a therapeutic agent. Its molecular weight is 657.62 g/mol, and it is soluble in organic solvents such as DMF and DCM. The compound is stable under dry conditions and should be stored at -20°C for long-term stability. No data on absorption, distribution, metabolism, or excretion are available, as these parameters are not relevant for a peptide synthesis building block.
|
| Toxicity/Toxicokinetics |
Toxicological data for this compound are limited. It should be handled with appropriate safety precautions, as it may be irritating to skin, eyes, and respiratory tract. The compound is stable under recommended storage conditions. No carcinogenic or reproductive toxicity data are available. Researchers should consult the safety data sheet for specific hazard information and handling guidelines. The compound is not intended for human use.
|
| Additional Infomation |
Fmoc-L-Ser((Ac)4-β-D-Glc)-OH is a glycosylated amino acid building block for solid-phase peptide synthesis. Its CAS number is 118358-38-6. The compound is used in glycobiology research for the synthesis of glycopeptides and glycoproteins. It is available with a purity of ≥98% from various suppliers. The compound is not approved for therapeutic use but is an essential tool for studying protein glycosylation and developing glycosylated therapeutics. It should be stored desiccated at -20°C to prevent degradation.
|
| Molecular Formula |
C32H35NO14
|
|---|---|
| Molecular Weight |
657.62
|
| Exact Mass |
657.205
|
| CAS # |
118358-38-6
|
| PubChem CID |
11125183
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
775.0±60.0 °C at 760 mmHg
|
| Flash Point |
422.5±32.9 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.590
|
| LogP |
5.46
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
47
|
| Complexity |
1140
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H](C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24)OC(=O)C)OC(=O)C)OC(=O)C
|
| InChi Key |
UGQPZVSWEMKXBN-UKFUGAQESA-N
|
| InChi Code |
InChI=1S/C32H35NO14/c1-16(34)41-15-26-27(44-17(2)35)28(45-18(3)36)29(46-19(4)37)31(47-26)42-14-25(30(38)39)33-32(40)43-13-24-22-11-7-5-9-20(22)21-10-6-8-12-23(21)24/h5-12,24-29,31H,13-15H2,1-4H3,(H,33,40)(H,38,39)/t25-,26+,27+,28-,29+,31+/m0/s1
|
| Chemical Name |
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxypropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5206 mL | 7.6032 mL | 15.2064 mL | |
| 5 mM | 0.3041 mL | 1.5206 mL | 3.0413 mL | |
| 10 mM | 0.1521 mL | 0.7603 mL | 1.5206 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
